{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T17:29:27Z","timestamp":1788802167525,"version":"build-2803163510"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>During the COVID-19 pandemic our center adjusted the standard induction therapy for normal immunological risk simultaneous pancreas-kidney (SPK) transplantations from T-cell depletion by alemtuzumab (ALEM) to IL-2 receptor blocking by basiliximab (IL2R). Here, we analyze the impact of this change on 1 year post-transplantation outcomes. Thirty-six adult patients who underwent SPK transplantation between June 2015 and June 2023 were included, of whom 21 before February 2020 (ALEM) and 15 after February 2020 (IL2R). Patients were stratified into two groups based on the induction therapy received. One death occurred during the follow up period. A total of three pancreas and two kidney grafts were lost. No differences between kidney and pancreas graft function or rejection rates were observed. Patients receiving IL2R induction had significantly lower 30\u00a0day postoperative complication rates (34 vs. 46%, <jats:italic>p<\/jats:italic>\u2009=\u20090.03) and experienced fewer bacterial infections (&lt;\u20096 months: 47 vs. 81%, <jats:italic>p<\/jats:italic>\u2009=\u20090.03). Additionally, lower rates of viral (including CMV) and fungal infections were observed. IL2R patients also had a significantly shorter hospital admission durations (14 vs. 30 days, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001). In conclusion, IL2R induction in SPK recipients was associated with similar short-term graft function and potentially improved outcomes compared to ALEM, warranting cautious interpretation due to sample size.<\/jats:p>","DOI":"10.1038\/s41598-025-06750-y","type":"journal-article","created":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T14:45:40Z","timestamp":1751381140000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Short-term outcome after simultaneous pancreas-kidney transplantation with alemtuzumab vs. basiliximab induction: a single-center retrospective study"],"prefix":"10.1038","volume":"15","author":[{"given":"Tim D. A.","family":"Swaab","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A.","family":"Pol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meindert J.","family":"Crop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan-Stephan F.","family":"Sanders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan P.","family":"Berger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hendrik S.","family":"Hofker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan J. L.","family":"Bakker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte A.","family":"te Velde-Keyzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,1]]},"reference":[{"key":"6750_CR1","unstructured":"Classification of diabetes mellitus. World Health Organization (2019)."},{"issue":"9677","key":"6750_CR2","doi-asserted-by":"publisher","first-page":"1808","DOI":"10.1016\/S0140-6736(09)60609-7","volume":"373","author":"SA White","year":"2009","unstructured":"White, S. A., Shaw, J. A. & Sutherland, D. E. Pancreas transplantation. Lancet 373 (9677), 1808\u20131817 (2009).","journal-title":"Lancet"},{"key":"6750_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/ajt.16738","volume":"21","author":"U Boggi","year":"2021","unstructured":"Boggi, U. et al. First world consensus conference on pancreas transplantation: part I\u2014methods and results of literature search. Am. J. Transpl. 21, 1\u201316 (2021).","journal-title":"Am. J. Transpl."},{"issue":"2","key":"6750_CR4","doi-asserted-by":"publisher","first-page":"132","DOI":"10.3390\/uro3020015","volume":"3","author":"AC Gruessner","year":"2023","unstructured":"Gruessner, A. C. A decade of pancreas transplantation\u2014a registry report. Uro 3(2), 132\u2013150 (2023).","journal-title":"Uro"},{"issue":"4","key":"6750_CR5","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1111\/ajt.12167","volume":"13","author":"M Dong","year":"2013","unstructured":"Dong, M. et al. Acute pancreas allograft rejection is associated with increased risk of graft failure in pancreas transplantation. Am. J. Transpl. 13(4), 1019\u20131025 (2013).","journal-title":"Am. J. Transpl."},{"issue":"11","key":"6750_CR6","doi-asserted-by":"publisher","first-page":"2945","DOI":"10.1111\/ajt.12443","volume":"13","author":"SV Niederhaus","year":"2013","unstructured":"Niederhaus, S. V. et al. Acute cellular and antibody-mediated rejection of the pancreas allograft: Incidence, risk factors and outcomes. Am. J. Transpl. 13(11), 2945\u20132955 (2013).","journal-title":"Am. J. Transpl."},{"issue":"7","key":"6750_CR7","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1111\/tri.12122","volume":"26","author":"SV Niederhaus","year":"2013","unstructured":"Niederhaus, S. V., Kaufman, D. B. & Odorico, J. S. Induction therapy in pancreas transplantation. Transpl. Int. 26(7), 704\u2013714 (2013).","journal-title":"Transpl. Int."},{"issue":"3","key":"6750_CR8","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.4049\/jimmunol.0903178","volume":"184","author":"J Du","year":"2009","unstructured":"Du, J. et al. Structural basis for the blockage of IL-2 signaling by therapeutic antibody Basiliximab. J. Immunol. 184(3), 1361\u20131368 (2009).","journal-title":"J. Immunol."},{"issue":"7","key":"6750_CR9","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1034\/j.1600-6143.2003.00160.x","volume":"3","author":"DB Kaufman","year":"2003","unstructured":"Kaufman, D. B. et al. Prospective, randomized, multi-center trial of antibody induction therapy in simultaneous pancreas\u2010kidney transplantation. Am. J. Transpl. 3(7), 855\u2013864 (2003).","journal-title":"Am. J. Transpl."},{"issue":"8","key":"6750_CR10","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1097\/01.TP.0000062838.38351.2A","volume":"75","author":"RJ Stratta","year":"2003","unstructured":"Stratta, R. J. et al. Two-dose daclizumab regimen in simultaneous kidney\u2010pancreas transplant recipients: primary endpoint analysis of a multicenter, randomized study. Transplantation 75(8), 1260\u20131266 (2003).","journal-title":"Transplantation"},{"issue":"12","key":"6750_CR11","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1097\/01.tp.0000250712.12389.3d","volume":"82","author":"NL Thai","year":"2006","unstructured":"Thai, N. L. et al. Alemtuzumab induction and tacrolimus monotherapy in pancreas transplantation: One- and two\u2010year outcomes. Transplantation 82(12), 1621\u20131624 (2006).","journal-title":"Transplantation"},{"issue":"10","key":"6750_CR12","doi-asserted-by":"publisher","first-page":"2126","DOI":"10.1111\/j.1600-6143.2008.02373.x","volume":"8","author":"AS Muthusamy","year":"2008","unstructured":"Muthusamy, A. S. et al. Alemtuzumab induction and steroid-free maintenance immunosuppression in pancreas transplantation. Am. J. Transpl. 8(10), 2126\u20132131 (2008).","journal-title":"Am. J. Transpl."},{"issue":"10","key":"6750_CR13","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1016\/S2468-2667(21)00200-0","volume":"6","author":"O Aubert","year":"2021","unstructured":"Aubert, O. et al. Covid-19 pandemic and worldwide organ transplantation: A population-based study. Lancet Public. Health. 6(10), 709\u2013719 (2021).","journal-title":"Lancet Public. Health"},{"issue":"10237","key":"6750_CR14","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/S0140-6736(20)31040-0","volume":"395","author":"A Loupy","year":"2020","unstructured":"Loupy, A. et al. Organ procurement and transplantation during the covid-19 pandemic. Lancet 395(10237), 95\u201396 (2020).","journal-title":"Lancet"},{"issue":"10","key":"6750_CR15","doi-asserted-by":"publisher","first-page":"2146","DOI":"10.1097\/TP.0000000000003873","volume":"105","author":"E Coll","year":"2021","unstructured":"Coll, E. et al. Covid-19 in solid organ transplant recipients in Spain throughout 2020: Catching the wave? Transplantation 105(10), 2146\u20132155 (2021).","journal-title":"Transplantation"},{"issue":"5","key":"6750_CR16","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","volume":"40","author":"M Charlson","year":"1987","unstructured":"Charlson, M., Pompei, P., Ales, K. & MacKenzie, C. A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. J. Chronic Dis. 40(5), 373\u2013383 (1987).","journal-title":"J. Chronic Dis."},{"issue":"2","key":"6750_CR17","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1097\/01.sla.0000133083.54934.ae","volume":"240","author":"D Dindo","year":"2004","unstructured":"Dindo, D., Demartines, N. & Clavien, P. A. Classification of surgical complications. Ann. Surg. 240(2), 205\u2013213 (2004).","journal-title":"Ann. Surg."},{"issue":"1","key":"6750_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/SLA.0b013e318296c732","volume":"258","author":"K Slankamenac","year":"2013","unstructured":"Slankamenac, K., Graf, R., Barkun, J., Puhan, M. A. & Clavien, P. A. The comprehensive complication index. Ann. Surg. 258(1), 1\u20137 (2013).","journal-title":"Ann. Surg."},{"issue":"9447","key":"6750_CR19","doi-asserted-by":"publisher","first-page":"1814","DOI":"10.1016\/S0140-6736(04)17406-0","volume":"364","author":"N Perico","year":"2004","unstructured":"Perico, N., Cattaneo, D., Sayegh, M. H. & Remuzzi, G. Delayed graft function in kidney transplantation. Lancet 364(9447), 1814\u20131827 (2004).","journal-title":"Lancet"},{"issue":"19","key":"6750_CR20","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1056\/NEJMoa2102953","volume":"385","author":"LA Inker","year":"2021","unstructured":"Inker, L. A. et al. New creatinine-and cystatin C\u2013based equations to estimate GFR without race. NEJM 385(19), 1737\u20131749 (2021).","journal-title":"NEJM"},{"issue":"1","key":"6750_CR21","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1900\/RDS.2011.8.6","volume":"8","author":"AC Gruessner","year":"2011","unstructured":"Gruessner, A. C. 2011 update on pancreas transplantation: Comprehensive trend analysis of 25,000 cases followed up over the course of twenty-four years at the international pancreas transplant registry (IPTR). Rev. Diabet. Studies: RDS. 8 (1), 6 (2011).","journal-title":"Rev. Diabet. Studies: RDS"},{"issue":"10","key":"6750_CR22","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1097\/01.tp.0000219235.97036.9c","volume":"81","author":"PJ Morris","year":"2006","unstructured":"Morris, P. J. & Russell, N. K. Alemtuzumab (campath-1\u00a0h): A systematic review in organ transplantation. Transplantation 81(10), 1361\u20131367 (2006).","journal-title":"Transplantation"},{"issue":"5","key":"6750_CR23","doi-asserted-by":"publisher","first-page":"2818","DOI":"10.4049\/jimmunol.1203261","volume":"191","author":"M Todeschini","year":"2013","unstructured":"Todeschini, M. et al. In kidney transplant patients, alemtuzumab but not basiliximab\/low-dose rabbit anti-thymocyte globulin induces B cell depletion and regeneration, which associates with a high incidence of de Novo donor-specific anti-HLA antibody development. J. Immunol. 191 (5), 2818\u20132828 (2013).","journal-title":"J. Immunol."},{"issue":"5","key":"6750_CR24","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1097\/01.TP.0000081042.67285.91","volume":"76","author":"WC Goggins","year":"2003","unstructured":"Goggins, W. C. et al. A prospective, randomized, clinical trial of intraoperative versus postoperative thymoglobulin in adult cadaveric renal transplant recipients. Transplantation 76 (5), 798\u2013802 (2003).","journal-title":"Transplantation"},{"issue":"7","key":"6750_CR25","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1097\/00007890-199904150-00013","volume":"67","author":"DC Brennan","year":"1999","unstructured":"Brennan, D. C. et al. A randomized, double-blinded comparison of thymoglobulin versus Atgam for induction immunosuppressive therapy in adult renal transplant recipients. Transplantation 67(7), 1011\u20131018 (1999).","journal-title":"Transplantation"},{"issue":"1","key":"6750_CR26","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1097\/00007890-199807150-00005","volume":"66","author":"AO Gaber","year":"1998","unstructured":"Gaber, A. O. et al. Results of the double-blind, randomized, multicenter, phase III clinical trial of thymoglobulin versus ATGAM in the treatment of acute graft rejection episodes after renal transplantation. Transplantation 66(1), 29\u201337 (1998).","journal-title":"Transplantation"},{"issue":"1","key":"6750_CR27","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1097\/01.TP.0000071362.99021.D9","volume":"76","author":"AD Kirk","year":"2003","unstructured":"Kirk, A. D. et al. Results from a human renal allograft tolerance trial evaluating the humanized CD52-specific monoclonal antibody alemtuzumab (CAMPATH-1H). Transplantation 76(1), 120\u2013129 (2003).","journal-title":"Transplantation"},{"issue":"6","key":"6750_CR28","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1097\/01.tp.0000166921.14670.33","volume":"80","author":"A Vathsala","year":"2005","unstructured":"Vathsala, A. et al. Randomized trial of alemtuzumab for prevention of graft rejection and preservation of renal function after kidney transplantation. Transplantation 80(6), 765\u2013774 (2005).","journal-title":"Transplantation"},{"issue":"9086","key":"6750_CR29","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1016\/S0140-6736(97)09278-7","volume":"350","author":"B Nashan","year":"1997","unstructured":"Nashan, B. et al. Randomised trial of Basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients. Lancet 350(9086), 1193\u20131198 (1997).","journal-title":"Lancet"},{"issue":"7","key":"6750_CR30","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1097\/00007890-200110150-00014","volume":"72","author":"C Ponticelli","year":"2001","unstructured":"Ponticelli, C. et al. A randomized, double-blind trial of basiliximab immunoprophylaxis plus triple therapy in kidney transplant recipients. Transplantation 72(7), 1261\u20131267 (2001).","journal-title":"Transplantation"},{"issue":"9955","key":"6750_CR31","doi-asserted-by":"publisher","first-page":"1684","DOI":"10.1016\/S0140-6736(14)61095-3","volume":"384","author":"R Haynes","year":"2014","unstructured":"Haynes, R. et al. Alemtuzumab-based induction treatment versus basiliximab-based induction treatment in kidney transplantation (the 3\u00a0C study): A randomised trial. Lancet 384 (9955), 1684\u20131690 (2014).","journal-title":"Lancet"},{"issue":"1","key":"6750_CR32","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.pan.2018.11.003","volume":"19","author":"S Benjamens","year":"2019","unstructured":"Benjamens, S. et al. A steady decline in pancreas transplantation rates. Pancreatology 19(1), 31\u201338 (2019).","journal-title":"Pancreatology"},{"issue":"2","key":"6750_CR33","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1111\/j.1600-6143.2005.01166.x","volume":"6","author":"DB Kaufman","year":"2006","unstructured":"Kaufman, D. B., Leventhal, J. R., Gallon, L. G. & Parker, M. A. Alemtuzumab induction and prednisone-free maintenance immunotherapy in simultaneous pancreas-kidney transplantation comparison with rabbit antithymocyte Globulin induction\u2013long-term results. Am. J. Transpl. 6(2), 331\u2013339 (2006).","journal-title":"Am. J. Transpl."},{"key":"6750_CR34","doi-asserted-by":"crossref","unstructured":"Reddy, K. S. et al. Alemtuzumab with rapid steroid taper in simultaneous kidney and pancreas transplantation: Comparison to induction with antithymocyte globulin. Transpl. Proc. 42(6), 2006\u20132008 (2010).","DOI":"10.1016\/j.transproceed.2010.05.090"},{"issue":"8","key":"6750_CR35","doi-asserted-by":"publisher","first-page":"1702","DOI":"10.1111\/j.1600-6143.2008.02299.x","volume":"8","author":"JF Magliocca","year":"2008","unstructured":"Magliocca, J. F. et al. A comparison of alemtuzumab with basiliximab induction in simultaneous pancreas\u2013kidney transplantation. Am. J. Transpl. 8 (8), 1702\u20131710 (2008).","journal-title":"Am. J. Transpl."},{"issue":"1","key":"6750_CR36","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1097\/TP.0b013e31818c6db0","volume":"87","author":"J Pascual","year":"2009","unstructured":"Pascual, J. et al. Alemtuzumab induction and antibody-mediated kidney rejection after simultaneous pancreas-kidney transplantation. Transplantation 87(1), 125\u2013132 (2009).","journal-title":"Transplantation"},{"key":"6750_CR37","doi-asserted-by":"crossref","unstructured":"Aziz, F., Parajuli, S., Kaufman, D., Odorico, J. & Mandelbrot, D. Induction in pancreas transplantation: T-cell depletion versus IL-2 receptor Blockade. Transpl. Direct 8(12), e1402 (2022).","DOI":"10.1097\/TXD.0000000000001402"},{"issue":"9","key":"6750_CR38","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1097\/TP.0b013e3182313e4f","volume":"92","author":"F Bazerbachi","year":"2011","unstructured":"Bazerbachi, F. et al. Thymoglobulin versus Basiliximab induction therapy for simultaneous kidney-pancreas transplantation: impact on rejection, graft function, and long-term outcome. Transplantation 92 (9), 1039\u20131043 (2011).","journal-title":"Transplantation"},{"issue":"1","key":"6750_CR39","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.transproceed.2014.12.003","volume":"47","author":"I Fern\u00e1ndez-Burgos","year":"2015","unstructured":"Fern\u00e1ndez-Burgos, I. et al. Induction therapy in simultaneous pancreas-kidney transplantation: thymoglobulin versus Basiliximab. Transpl. Proc. 47(1), 120\u2013122 (2015).","journal-title":"Transpl. Proc."},{"key":"6750_CR40","doi-asserted-by":"crossref","unstructured":"Cerise, A. et al. Outcomes of primary simultaneous Pancreas-kidney transplants by induction agent in the united States. Transpl. Direct 8(12), e1412 (2022).","DOI":"10.1097\/TXD.0000000000001412"},{"issue":"5","key":"6750_CR41","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1111\/j.1432-2277.2008.00788.x","volume":"22","author":"T Haudebourg","year":"2009","unstructured":"Haudebourg, T., Poirier, N. & Vanhove, B. Depleting T-cell subpopulations in organ transplantation. Transpl. Int. 22(5), 509\u2013518 (2009).","journal-title":"Transpl. Int."},{"issue":"3","key":"6750_CR42","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1111\/j.1600-6143.2005.00759.x","volume":"5","author":"JP Pearl","year":"2005","unstructured":"Pearl, J. P. et al. Immunocompetent T-cells with a memory-like phenotype are the dominant cell type following antibody-mediated T-cell depletion. Am. J. Transpl. 5(3), 465\u2013474 (2005).","journal-title":"Am. J. Transpl."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-06750-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-06750-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-06750-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T14:45:42Z","timestamp":1751381142000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-06750-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,1]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["6750"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-06750-y","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,1]]},"assertion":[{"value":"22 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no financial or non-financial competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"20732"}}